Phase II clinical trial of the combination of eribulin and trastuzumab for advanced/recurrent HER2-positive breast cancer
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Eribulin (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Jul 2018 Primary endpoint ( Response Rate (RR) ) has been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 01 Jul 2018 Results (n=28) published in the Anticancer Research.
- 05 Jun 2018 Results (n=28) presented at the 54th Annual Meeting of the American Society of Clinical Oncology